✦ LIBER ✦

Enhancement of gefitinib-induced growth inhibition byMarsdenia tenacissimaextract in non-small cell lung cancer cells expressing wild or mutant EGFR

✍ Scribed by Han, Shu-Yan; Ding, Hui-Rong; Zhao, Wei; Teng, Fei; Li, Ping-Ping

Book ID: 125400035
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 667 KB
Volume: 14
Category: Article
ISSN: 1472-6882
DOI: 10.1186/1472-6882-14-165

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hypoxia induces gefitinib resistance in

Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors

✍ Kunihiko Minakata; Fumiyuki Takahashi; Takeshi Nara; Muneaki Hashimoto; Ken Taji 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 639 KB

Re-expression of TSLC1 in a non-small-ce

Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth

✍ Mao, Xinliang; Seidlitz, Eric; Truant, Ray; Hitt, Mary; Ghosh, Hara P 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 550 KB

Enhanced cytotoxicity induced by gefitin

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells

✍ Maarten L. Janmaat; José A. Rodriguez; Mariëlle Gallegos-Ruiz; Frank A.E. Kruyt; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 371 KB

## Abstract In this study, we have characterized a panel of NSCLC cell lines with differential sensitivity to gefitinib for activating mutations in __egfr__, __pik3ca__, and __k‐ras__, and basal protein expression levels of PTEN. The __egfr__ mutant NSCLC cell line H1650 as well as the __egfr__ wil

55 Randomized phase II clinical trial of

55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

✍ R. Rosell; R. Ramlau; A. Szczesna; C. Daniel; M. Bertrand; R. Garcia-Arroyo; K. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

9019 POSTER DISCUSSION Safety Analysis o

9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy

✍ von Pawel, J.; Pirker, R.; Pereira, J.R.; Krzakowski, M.; Park, K.; Eberhardt, W 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB